Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

ContextLong-acting recombinant human growth hormone (rhGH) has transformed growth hormone deficiency (GHD) treatment. However, the possibility and rationality for flexible time regimen are pending.ObjectiveWe studied the efficacy of biweekly versus weekly PEGylated rhGH (PEG-rhGH) therapy in GHD chi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chengjun Sun, Biao Lu, Yu Liu, Yaqin Zhang, Haiyan Wei, Xu Hu, Pei Hu, Qian Zhao, Yanling Liu, Kan Ye, Kan Wang, Zaiyan Gu, Zheng Liu, Jin Ye, Hongxiao Zhang, Hong Zhu, Zhihong Jiang, Yanjie Liu, Naijun Wan, Chengming Yan, Jianying Yin, Lirong Ying, Feng Huang, Qingjin Yin, Li Xi, Feihong Luo, Ruoqian Cheng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2021-11-01
Serie:	Frontiers in Endocrinology
Soggetti:	growth hormone deficiency PEGylated recombinant human growth hormone PEG-rhGH IGF-2 children
Accesso online:	https://www.frontiersin.org/articles/10.3389/fendo.2021.779365/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!